Macular edema post-LASIK treated with ranibizumab

Edema cistóide de mácula pós-LASIK tratado com ranibizumabe

Luiz Guilherme Azevedo de Freitas¹, Natália Silva de Mesquita², Juliana Aquino Teixeira Zorrilla², Marcos Pereira de Ávila³

ABSTRACT

The authors report the case of a patient who developed cystoid macular edema after surgery for myopia by LASIK method. She was treated with intravitreal injections of ranibizumab and presented satisfactory visual result.

Keywords: Macular edema/etiology; Keratomileusis, laser in situ; Angiogenesis inhibitors; Case reports

RESUMO

Os autores relatam o caso de uma paciente que desenvolveu edema cistóide de mácula pós-cirurgia para correção de miopia pelo método LASIK. Foi submetida a tratamento com injeções intravitrea de ranibizumabe e apresentou resultado visual satisfatório.

Descritores: Edema macular/etiologia; Ceratomileuse assistida por excimer laser in situ; Inibidores da angiogênese; Relatos de casos

¹ Retina and Vitreous Department, Santa Luzia Eye Hospital, Recife/PE, Brazil; Post-Graduation Programme in Health Science, Federal University of Goiás, Goiânia/GO, Brazil.
² Residence Programme in Ophthalmology, Santa Luzia Eye Hospital, Recife/PE, Brazil.
³ Federal University of Goiás, Goiânia/GO, Brazil; Reference Centre in Ophthalmology, Goiânia/GO, Brazil.

Institution: Santa Luzia Eye Hospital, Recife/PE, Brazil.

The authors declare no conflict of interest.

Received for publication 19/9/2013 - Accepted for publication 23/2/2014
INTRODUCTION

Laser in situ keratomileusis (LASIK) is a surgical procedure used to correct refractive errors with high levels of safety and efficacy.1,2 Most post-LASIK complications are related to the refractive outcome or to damage to the cornea and anterior segment. The posterior segment is rarely damaged.3

Excessive mechanical stress has been suggested as a cause of vitreoretinal complications during or after LASIK. Changes occur during application of the suction ring to hold the eyeball while creating the corneal flap.1 This exerts an anterior vector force on the vitreous body where the anterior hyaloid membrane attaches to the posterior lens capsule. The induced traction can act on areas of high vitreoretinal adhesion (vitreous base and macula) causing retinal rupture and macular hole. In areas of low vitreoretinal adhesion, the vector force can cause vitreous detachment.4-7

Another factor is the time required to create the flap. Prolonged suction can be associated with a high incidence of complications, including posterior segment ischemia due to increased intraocular pressure (IOP).

In LASIK, the microkeratome is the main element related to posterior segment complications, and not excimer laser itself. Posterior vitreous detachment, rhegmatogenous retinal detachment and choroidal neovascularisation with macular haemorrhage are all associated with LASIK, with high myopia as the main risk factor.6,8 Macular hole and cystoid macular oedema (CMO) occur within the first six postoperative months and are more common in female patients.10,11 Diseases of the optic nerve, visual field defects and vascular events are associated with high IOP while using the microkeratome.12 Other complications associated with LASIK include uveal effusion syndrome, serous detachment of the macula, central serous chorioretinopathy, bilateral choroidal infarction, and reactivation of ocular toxoplasmosis.13-16

Despite the large number of refractive surgeries performed each year and the presence of mechanisms responsible for posterior segment complications after LASIK, the incidence of such events is low. Candidates for the procedure should be aware that such complications exist and should undergo fundus examination before and after surgery.

CASE REPORT

A 52-year-old female patient underwent LASIK in both eyes (BE) in February 2011. Prior to the surgical procedure she had myopia in both eyes. Two months after surgery she presented low visual acuity (LVA) in the right eye (RE).

She sought our Vitreous and Retina Department one year after surgery. She reported having received treatment soon after the onset of symptoms in the RE. She was treated with ketorolac tromethamine (Acular LS, Allergan) 4 times daily for 3 months, without visual improvement.

Ophthalmic examination showed a best corrected visual acuity of 20/40 in the RE 20/20 in the LE. Biomicroscopy found no changes that could explain the LVA.

Retinal mapping of the RE showed macular discolouration and a thinned retinal pigment epithelium in the fovea. The LE had no macular changes.

Fluorescein angiography of the RE showed macular hyperfluorescence. Optical coherence tomography (OCT) of the RE showed a fluid-filled cystoid space in the macular region characteristic of cystoid macular oedema (ECM) (Figure 1).

Treatment with intravitreal injections of ranibizumab was indicated.

The first injection was applied in February 2012. An OCT performed 58 days after the injection already showed a flat foveal depression and the presence of small cystic spaces (Figure 2).

We opted for a new intravitreal injection of ranibizumab in the RE. One month after the second injection, the patient reported a decrease in visual acuity. A new OCT was done, finding a relapse of CMO. Another 3 ranibizumab injections were prescribed, one per month. After the second injection (the fourth in total) a significant reduction of the cyst was noted, without interruption of the internal limiting membrane (Figure 3).

After the fifth and final injection the patient’s visual acuity improved to 20/25 in the RE, and OCT showed a normal foveal depression. The patient then underwent follow up with visits every 6 months (Figure 3).

On examination 6 months after the last ranibizumab injection the patient’s visual acuity remained 20/25 in the RE and 20/20 in the LE. OCT found no anatomical changes in the macula (Figure 3).
**DISCUSSION**

Surgery to correct refractive errors is becoming increasingly common. LASIK procedures are considered to be safe, but are not exempt from postoperative complications. Lin and collaborators reported in 2005 a case of bilateral cystoid macular oedema treated with oral corticosteroids. In our case, we opted not to use corticosteroids because ranibizumab has been showing positive results, and corticosteroids could cause undesirable effects such as increased intraocular pressure and cataract.

Initially it was thought that the patient had a macular microhole, which could explain the relapse of macular fluid. OCT with a high number of slices and in 3D was performed to assess this possibility. This differential diagnosis had to be discarded because the oedema's pathophysiology and treatment would be entirely different, and ranibizumab would not be effective. The presence of a microhole was discarded, therefore anti-VEGF therapy was resumed.

After a series of injections the patient responded with complete resolution of the oedema, and 6 months after the last injection her macular anatomy remained normal.

The result obtained here suggests that treatment with intravitreal injections of ranibizumab can be effective in patients with CMO after LASIK.

**REFERENCES**


**Corresponding author:**
Luiz Guilherme Freitas
Estrada do Encanamento, 909.
Casa Forte, Recife/PE, Brazil
CEP: 52070-010